It is noteworthy that a significant proportion of patients with PSC-IBD (31.2%, 95% CI: 23.8–39.7) had an endoscopic IBD response, which was 2-fold higher for vedolizumab (46.3%, 95% CI: 32.2–61.1) compared to the anti-TNF alpha inhibitors (23.2%, 95% CI: 15.8–32.7, p<0.01). Here, TNF is linked to inflammatory bowel disease.